Despite posting record Q2 growth for its blockbuster weight loss and diabetes drug tirzepatide, Eli Lilly is facing legal ...

Eli Lilly’s weight-loss pill disappointed in a key trial, but CEO David Ricks and other insiders together bought nearly $3 ...

Texas AG Ken Paxton sues Eli Lilly for alleged bribery to promote diabetes drugs, claiming violation of state fraud laws and ...

Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant ...

Paxton's office said the company supplied free nurses to help care for patients who received its drugs, as well as ...

Texas Attorney General Ken Paxton claims that through an alleged kickback scheme Eli Lilly “fraudulently sought to maximize profits at taxpayer expense.” ...

WASHINGTON (Reuters) -Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly "bribing" ...

Eli Lilly and Company faces valuation pressure after disappointing Orforglipron results. Discover why now isn't the time to ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

The company said it planned to seek Food and Drug Administration approval for the drug, orforglipron, before the end of the ...